Format

Send to

Choose Destination
Ann Clin Transl Neurol. 2018 May 26;5(7):883-887. doi: 10.1002/acn3.584. eCollection 2018 Jul.

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD.

Author information

1
Department of Psychiatry and Psychotherapy Universitätsklinikum Erlangen, and Friedrich-Alexander-Universität Erlangen-Nürnberg Erlangen Germany.
2
Department of Neurodegeneration Diagnostics Medical University of Białystok Białystok Poland.
3
Department of Biochemical Diagnostics University Hospital of Białystok Białystok Poland.
4
Clinical Dementia Center Department of Neurology University Medical School Göttingen Germany.
5
German Center for Neurodegenerative Diseases (DZNE) Göttingen Germany.
6
Network Center for Biomedical Research in Neurodegenerative Diseases Barcelona (CIBERNED) Institute Carlos III Ministry of Health Bellvitge Spain.

Abstract

Creutzfeldt-Jakob disease and Alzheimer's disease are characterized by the presence of elevated total-Tau cerebrospinal fluid concentrations while the presence of hyperphosphorylated Tau forms in the cerebrospinal fluid is rather a hallmark of Alzheimer's disease. Here we aimed to investigate potential contribution of nonphospho-Tau epitopes (non-P-Tau) in the discrimination between both diseases. Non-P-Tau cerebrospinal fluid concentration was highly increased in Creutzfeldt-Jakob disease (n = 57, 3683 ± 3599 pg/mL) compared to Alzheimer's disease (n = 41, 148 ± 219 pg/mL) and neurological controls (n = 56, 62 ± 40 pg/mL), and significantly improved the proportion of correctly classified patients (99%) compared to that achieved by total-Tau (90%), P-Tau (62%) and 14-3-3 (91%).

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center